Which has better earnings & valuation, BVS or INFU?

Bioventus has higher revenue and earnings than InfuSystem. Bioventus is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.26 $22.73M $0.41 20.85 InfuSystem $142.40M 1.28 $870K $0.38 23.76

Is BVS or INFU more profitable?

Bioventus has a net margin of 4.94% compared to InfuSystem's net margin of 1.12%. Bioventus' return on equity of 29.97% beat InfuSystem's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% InfuSystem 1.12% 2.78% 1.41%

Which has preferable valuation and earnings, INFU or CBLL?

InfuSystem has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $142.40M 1.28 $870K $0.38 23.76 CeriBell $89.06M 7.32 -$53.41M -$1.63 N/A

Is INFU or CBLL more profitable?

InfuSystem has a net margin of 1.12% compared to CeriBell's net margin of -63.51%. InfuSystem's return on equity of 2.78% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% CeriBell -63.51% -38.19% -30.92%

Which has stronger valuation and earnings, INFU or SGP?

InfuSystem has higher revenue and earnings than Spyglass Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $142.40M 1.28 $870K $0.38 23.76 Spyglass Pharma N/A N/A N/A N/A N/A

Which has stronger earnings & valuation, SIBN or INFU?

InfuSystem has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.07 -$18.90M -$0.39 N/A InfuSystem $142.40M 1.28 $870K $0.38 23.76

Is SIBN or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to SiBone's net margin of -8.10%. InfuSystem's return on equity of 2.78% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% InfuSystem 1.12% 2.78% 1.41%

InfuSystem (INFU) Competitors

$9.03 +0.15 (+1.69%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$9.02 -0.01 (-0.11%)

As of 06/3/2026 04:12 PM Eastern

Compare

INFU vs. SSII, BVS, CBLL, SGP, and SIBN

Should you buy InfuSystem stock or one of its competitors? MarketBeat compares InfuSystem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InfuSystem include SS Innovations International (SSII), Bioventus (BVS), CeriBell (CBLL), Spyglass Pharma (SGP), and SiBone (SIBN). These companies are all part of the "medical equipment" industry.

How does InfuSystem compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and InfuSystem (NYSE:INFU) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

SS Innovations International presently has a consensus price target of $7.00, suggesting a potential upside of 62.41%. InfuSystem has a consensus price target of $15.00, suggesting a potential upside of 66.11%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts clearly believe InfuSystem is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, SS Innovations International had 1 more articles in the media than InfuSystem. MarketBeat recorded 1 mentions for SS Innovations International and 0 mentions for InfuSystem. SS Innovations International's average media sentiment score of 1.89 beat InfuSystem's score of 1.00 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Overall Sentiment
SS Innovations International	Very Positive
InfuSystem	Positive

SS Innovations International has a beta of -1.88, indicating that its share price is 288% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

71.1% of InfuSystem shares are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

InfuSystem has a net margin of 1.12% compared to SS Innovations International's net margin of -20.69%. InfuSystem's return on equity of 2.78% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
InfuSystem	1.12%	2.78%	1.41%

InfuSystem has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	20.30	-$12.13M	-$0.05	N/A
InfuSystem	$142.40M	1.28	$870K	$0.38	23.76

Summary

InfuSystem beats SS Innovations International on 13 of the 16 factors compared between the two stocks.

How does InfuSystem compare to Bioventus?

Bioventus (NASDAQ:BVS) and InfuSystem (NYSE:INFU) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Bioventus has higher revenue and earnings than InfuSystem. Bioventus is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.26	$22.73M	$0.41	20.85
InfuSystem	$142.40M	1.28	$870K	$0.38	23.76

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 33.0% of Bioventus shares are owned by company insiders. Comparatively, 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Bioventus had 2 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for Bioventus and 0 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.00 beat Bioventus' score of 0.47 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
Bioventus	Neutral
InfuSystem	Positive

Bioventus has a net margin of 4.94% compared to InfuSystem's net margin of 1.12%. Bioventus' return on equity of 29.97% beat InfuSystem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
InfuSystem	1.12%	2.78%	1.41%

Bioventus currently has a consensus target price of $14.00, indicating a potential upside of 63.74%. InfuSystem has a consensus target price of $15.00, indicating a potential upside of 66.11%. Given InfuSystem's higher probable upside, analysts clearly believe InfuSystem is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Bioventus has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Summary

Bioventus beats InfuSystem on 11 of the 17 factors compared between the two stocks.

How does InfuSystem compare to CeriBell?

InfuSystem (NYSE:INFU) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

InfuSystem has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.28	$870K	$0.38	23.76
CeriBell	$89.06M	7.32	-$53.41M	-$1.63	N/A

InfuSystem currently has a consensus price target of $15.00, suggesting a potential upside of 66.11%. CeriBell has a consensus price target of $22.20, suggesting a potential upside of 29.22%. Given InfuSystem's higher probable upside, analysts clearly believe InfuSystem is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, CeriBell had 3 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for CeriBell and 0 mentions for InfuSystem. CeriBell's average media sentiment score of 1.38 beat InfuSystem's score of 1.00 indicating that CeriBell is being referred to more favorably in the news media.

Company	Overall Sentiment
InfuSystem	Positive
CeriBell	Positive

71.1% of InfuSystem shares are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Comparatively, 20.1% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

InfuSystem has a net margin of 1.12% compared to CeriBell's net margin of -63.51%. InfuSystem's return on equity of 2.78% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
CeriBell	-63.51%	-38.19%	-30.92%

InfuSystem has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Summary

InfuSystem beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does InfuSystem compare to Spyglass Pharma?

InfuSystem (NYSE:INFU) and Spyglass Pharma (NASDAQ:SGP) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Spyglass Pharma had 13 more articles in the media than InfuSystem. MarketBeat recorded 13 mentions for Spyglass Pharma and 0 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.00 beat Spyglass Pharma's score of 0.38 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Positive
Spyglass Pharma	Neutral

71.1% of InfuSystem shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

InfuSystem has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.28	$870K	$0.38	23.76
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

InfuSystem has a net margin of 1.12% compared to Spyglass Pharma's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Spyglass Pharma	N/A	N/A	N/A

InfuSystem presently has a consensus price target of $15.00, suggesting a potential upside of 66.11%. Spyglass Pharma has a consensus price target of $45.00, suggesting a potential upside of 142.46%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

InfuSystem beats Spyglass Pharma on 7 of the 11 factors compared between the two stocks.

How does InfuSystem compare to SiBone?

SiBone (NASDAQ:SIBN) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

SiBone has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

In the previous week, SiBone had 6 more articles in the media than InfuSystem. MarketBeat recorded 6 mentions for SiBone and 0 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.00 beat SiBone's score of 0.19 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
SiBone	Neutral
InfuSystem	Positive

98.1% of SiBone shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

InfuSystem has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.07	-$18.90M	-$0.39	N/A
InfuSystem	$142.40M	1.28	$870K	$0.38	23.76

InfuSystem has a net margin of 1.12% compared to SiBone's net margin of -8.10%. InfuSystem's return on equity of 2.78% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
InfuSystem	1.12%	2.78%	1.41%

SiBone currently has a consensus target price of $23.00, suggesting a potential upside of 65.23%. InfuSystem has a consensus target price of $15.00, suggesting a potential upside of 66.11%. Given InfuSystem's higher possible upside, analysts plainly believe InfuSystem is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

InfuSystem beats SiBone on 10 of the 16 factors compared between the two stocks.

Get InfuSystem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INFU vs. The Competition

Export

Metric	InfuSystem	Surgical & medical instruments Industry	Medical Sector	NYSE Exchange
Market Cap	$182.24M	$45.18M	$6.47B	$23.28B
Dividend Yield	N/A	1.08%	2.69%	4.06%
P/E Ratio	150.53	15.70	22.39	31.00
Price / Sales	1.28	32.21	520.79	23.82
Price / Cash	12.79	18.87	41.34	24.93
Price / Book	3.66	15.95	9.84	4.67
Net Income	$870K	-$19.55M	$3.57B	$1.07B
7 Day Performance	-0.33%	-3.69%	-2.46%	-1.10%
1 Month Performance	N/A	N/A	N/A	0.25%
1 Year Performance	48.03%	-10.21%	26.49%	25.20%

InfuSystem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INFU InfuSystem	4.1626 of 5 stars	$9.03 +1.7%	$15.00 +66.1%	+49.0%	$182.24M	$142.40M	150.53	410	Positive News
SSII SS Innovations International	2.6479 of 5 stars	$3.73 -4.1%	N/A	-24.5%	$778.51M	$42.49M	N/A	4	Positive News Analyst Forecast
BVS Bioventus	4.3055 of 5 stars	$9.02 -2.8%	$14.00 +55.2%	N/A	$775.20M	$568.09M	22.00	1,200
CBLL CeriBell	2.7025 of 5 stars	$18.80 +0.2%	$22.20 +18.1%	+1.5%	$712.18M	$89.06M	N/A	N/A
SGP Spyglass Pharma	N/A	$20.62 -1.1%	$45.00 +118.2%	N/A	$689.39M	N/A	N/A	65	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INFU) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InfuSystem (INFU) Competitors

INFU vs. SSII, BVS, CBLL, SGP, and SIBN

How does InfuSystem compare to SS Innovations International?

Summary

How does InfuSystem compare to Bioventus?

Summary

How does InfuSystem compare to CeriBell?

Summary

How does InfuSystem compare to Spyglass Pharma?

Summary

How does InfuSystem compare to SiBone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InfuSystem (INFU) Competitors

INFU vs. SSII, BVS, CBLL, SGP, and SIBN

How does InfuSystem compare to SS Innovations International?

Do analysts prefer SSII or INFU?

Does the media prefer SSII or INFU?

Which has more risk and volatility, SSII or INFU?

Do insiders and institutionals believe in SSII or INFU?

Is SSII or INFU more profitable?

Which has preferable earnings & valuation, SSII or INFU?

Summary

How does InfuSystem compare to Bioventus?

Which has better earnings & valuation, BVS or INFU?

Do insiders & institutionals have more ownership in BVS or INFU?

Does the media prefer BVS or INFU?

Is BVS or INFU more profitable?

Do analysts prefer BVS or INFU?

Which has more volatility & risk, BVS or INFU?

Summary

How does InfuSystem compare to CeriBell?

Which has preferable valuation and earnings, INFU or CBLL?

Do analysts recommend INFU or CBLL?

Does the media favor INFU or CBLL?

Do institutionals and insiders hold more shares of INFU or CBLL?

Is INFU or CBLL more profitable?

Which has more risk & volatility, INFU or CBLL?

Summary

How does InfuSystem compare to Spyglass Pharma?

Does the media favor INFU or SGP?

Do institutionals and insiders have more ownership in INFU or SGP?

Which has stronger valuation and earnings, INFU or SGP?

Is INFU or SGP more profitable?

Do analysts rate INFU or SGP?

Summary

How does InfuSystem compare to SiBone?

Which has more volatility and risk, SIBN or INFU?

Does the media prefer SIBN or INFU?

Do institutionals and insiders hold more shares of SIBN or INFU?

Which has stronger earnings & valuation, SIBN or INFU?

Is SIBN or INFU more profitable?

Do analysts recommend SIBN or INFU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools